Cost per Opioid-Free Year: A Systematic Review and Summary Analysis.

IF 6 2区医学 Q1 ECONOMICS

Value in Health Pub Date : 2025-07-22 DOI:10.1016/j.jval.2025.07.008

Babasoji E Oyemakinde, Danielle Ryan, Techna Cadet, Tyler Judge, Manesh Gopaldas, Ali Jalali, Sean M Murphy

{"title":"Cost per Opioid-Free Year: A Systematic Review and Summary Analysis.","authors":"Babasoji E Oyemakinde, Danielle Ryan, Techna Cadet, Tyler Judge, Manesh Gopaldas, Ali Jalali, Sean M Murphy","doi":"10.1016/j.jval.2025.07.008","DOIUrl":null,"url":null,"abstract":"Objectives: Opioids remain a leading cause of death in the United States, and time free from opioid use is a common measure of effectiveness in economic evaluations of opioid use disorder (OUD) interventions. This study reviews the economic evaluation literature on OUD, identifies studies that calculated incremental cost-effectiveness ratios (ICER) based on time free from opioids, and establishes a benchmark for comparison in future research.Methods: The review examined economic evaluations of OUD interventions published in the peer-reviewed literature from inception to September 2024. ICERs of cost per period of opioid-free time were extracted or calculated from studies meeting the inclusion criteria. Monetary values were converted to 2024 USD and ICERs normalized to cost per opioid-free year (OfY). Articles were classified by intervention location (United States vs international) and economic perspective.Results: Fourteen articles met the inclusion criteria: 8 from the United States, 4 from Australia, 1 from Malaysia, and 1 from the United Kingdom. Among the US-based studies, the average ICER per OfY for the healthcare-sector, the state policymaker, and the societal perspective were $243 053/OfY, $17 674/OfY, and $32 125/OfY, respectively. For international studies, average ICERs for the healthcare-sector and societal perspectives were $79 765/OfY and $195 980/OfY, respectively.Conclusions: Cost per OfY is a widely used metric in economic evaluations because of its relative importance as a measure of clinical effectiveness. However, a universally accepted benchmark for decision making does not yet exist. This review aggregates data from existing studies that provided this measure, offering an initial step for establishing a cost-effectiveness threshold for cost per OfY.","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406688/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jval.2025.07.008","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Opioids remain a leading cause of death in the United States, and time free from opioid use is a common measure of effectiveness in economic evaluations of opioid use disorder (OUD) interventions. This study reviews the economic evaluation literature on OUD, identifies studies that calculated incremental cost-effectiveness ratios (ICER) based on time free from opioids, and establishes a benchmark for comparison in future research.

Methods: The review examined economic evaluations of OUD interventions published in the peer-reviewed literature from inception to September 2024. ICERs of cost per period of opioid-free time were extracted or calculated from studies meeting the inclusion criteria. Monetary values were converted to 2024 USD and ICERs normalized to cost per opioid-free year (OfY). Articles were classified by intervention location (United States vs international) and economic perspective.

Results: Fourteen articles met the inclusion criteria: 8 from the United States, 4 from Australia, 1 from Malaysia, and 1 from the United Kingdom. Among the US-based studies, the average ICER per OfY for the healthcare-sector, the state policymaker, and the societal perspective were $243 053/OfY, $17 674/OfY, and $32 125/OfY, respectively. For international studies, average ICERs for the healthcare-sector and societal perspectives were $79 765/OfY and $195 980/OfY, respectively.

Conclusions: Cost per OfY is a widely used metric in economic evaluations because of its relative importance as a measure of clinical effectiveness. However, a universally accepted benchmark for decision making does not yet exist. This review aggregates data from existing studies that provided this measure, offering an initial step for establishing a cost-effectiveness threshold for cost per OfY.

查看原文本刊更多论文

无阿片类药物年成本：系统回顾和总结分析。

目的：阿片类药物仍然是美国死亡的主要原因，阿片类药物使用的时间自由是阿片类药物使用障碍（OUD）干预措施经济评估有效性的常见措施。本研究回顾了OUD的经济评估文献，确定了基于无阿片类药物时间计算增量成本-效果比（ICER）的研究，并为未来研究的比较建立了基准。方法：本综述回顾了同行评议文献中发表的从开始到2024年9月的OUD干预措施的经济评价。从符合纳入标准的研究中提取或计算每段无阿片类药物时间的成本ICERs。货币价值转换为2024美元，ICERs标准化为每无阿片类药物年（OfY）的成本。文章按干预地点（美国与国际）和经济视角进行分类。结果：14篇文章符合纳入标准：8篇来自美国，4篇来自澳大利亚，1篇来自马来西亚，1篇来自英国。在以美国为基础的研究中，医疗保健部门、国家决策者和社会视角的平均每OfY ICER分别为243,053美元/OfY、17,674美元/OfY和32,125美元/OfY。在国际研究中，医疗保健部门和社会观点的平均ICERs分别为79,765美元/年和195,980美元/年。结论：由于其作为临床有效性衡量指标的相对重要性，每OfY成本在经济评估中被广泛使用。但是，目前还没有一个普遍接受的决策基准。本综述汇总了提供该措施的现有研究的数据，为建立每OfY成本的成本效益阈值提供了初步步骤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Value in Health 医学-卫生保健

CiteScore

6.90

自引率

6.70%

发文量

3064

审稿时长

3-8 weeks

期刊介绍： Value in Health contains original research articles for pharmacoeconomics, health economics, and outcomes research (clinical, economic, and patient-reported outcomes/preference-based research), as well as conceptual and health policy articles that provide valuable information for health care decision-makers as well as the research community. As the official journal of ISPOR, Value in Health provides a forum for researchers, as well as health care decision-makers to translate outcomes research into health care decisions.